newsfilter
← Latest News
GlobeNewswire·

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the